Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

Recent & Breaking News (NDAQ:PMN)

ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer's Disease with Selectivity for the Neurotoxic Form of Tau

Canada NewsWire May 28, 2019

ProMIS Drug Platform Sees Value Expatiated in Q1 2019

Stockhouse Editorial May 14, 2019

ProMIS Neurosciences Announces First Quarter 2019 Results

Canada NewsWire May 14, 2019

ProMIS Neurosciences to Participate in the Think Equity Investor Conference

Canada NewsWire April 23, 2019

Positive Results and New Technology Give Rise to Antibody Dominance

GlobeNewswire March 27, 2019

ProMIS to Present Discoveries at NY Microcap Conference

Stockhouse Editorial March 26, 2019

ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019

Canada NewsWire March 26, 2019

Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease

Canada NewsWire March 21, 2019

ProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson's Disease at AD/PD™ 2019 Conference

Canada NewsWire March 19, 2019

ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results

Canada NewsWire March 15, 2019

Attacking the Right Therapeutic Target in Alzheimer’s Disease

Featured Submission March 4, 2019

ProMIS Neurosciences Adds Pharmaceutical Leader Timothy Rothwell to Board of Advisors

PR Newswire February 21, 2019

Antibody Candidates Targeting Parkinson’s Disease Identified

Stockhouse Editorial February 12, 2019

Parkinson's Disease: ProMIS Neurosciences Identifies Several Antibody Drug Candidates Showing Best-in-Class Selectivity for Toxic Forms of Alpha-Synuclein Compared to other Therapeutic Antibodies in Development

Canada NewsWire February 12, 2019

Parkinson's Disease: ProMIS Neurosciences Identifies Several Antibody Drug Candidates Showing Best-in-Class Selectivity for Toxic Forms of Alpha-Synuclein Compared to other Therapeutic Antibodies in Development

Canada NewsWire February 12, 2019

Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer's Disease

Canada NewsWire January 31, 2019

Shooting to the Top: HUGE Growth Numbers for Esports

Jeff Nielson January 28, 2019

ProMis Completes $2.2 Million Private Placement

Stockhouse Editorial January 23, 2019

ProMIS Neurosciences Completes Private Placement of Units

Canada NewsWire January 23, 2019

ProMIS Neurosciences Heading to NobleCon15 & CanTech

Stockhouse Editorial January 17, 2019